Joshua Hexter sold $135k of ORMP
COO & CBO at ORAMED PHARMACEUTICALS INC.. 30,000 shares at an average of $4.51, traded Oct 1, 2026, filed Oct 2, 2026.
Score components
- +20RoleCOO
- +11Trade size$135k at market
- 0Share of holdings soldSold 2.2% of holdings
- +8Cluster2 insiders selling within 14 days
- -2010b5-1 planPre-scheduled under a 10b5-1 plan
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0001213900-26-106530, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Oct 1, 2026 | SOpen-market sale Common Stock10b5-1 | -30,000 | $4.51 | $135k | 1,328,130 | 10 d ago |
Related signals
Other insiders at ORAMED PHARMACEUTICALS INC. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | ORAMED PHARMACEUTICALS INC. | Avraham Gabay Chief Financial Officer | $90k 20,000 shares | -2% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.